ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Get Free Report) shares were up 6% during mid-day trading on Wednesday . The company traded as high as $1.99 and last traded at $1.93. Approximately 1,431,610 shares traded hands during mid-day trading, a decline of 45% from the average daily volume of 2,620,055 shares. The stock had previously closed at $1.82.
Analyst Upgrades and Downgrades
A number of analysts have commented on IPA shares. Wall Street Zen upgraded shares of ImmunoPrecise Antibodies to a "sell" rating in a research note on Saturday, May 24th. Benchmark reissued a "speculative buy" rating and set a $3.00 target price on shares of ImmunoPrecise Antibodies in a research report on Tuesday, April 1st. Finally, HC Wainwright restated a "buy" rating and issued a $5.00 target price on shares of ImmunoPrecise Antibodies in a report on Friday, April 11th.
View Our Latest Stock Report on ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Price Performance
The firm has a market cap of $79.16 million, a P/E ratio of -1.49 and a beta of 0.44. The company has a fifty day moving average of $0.93 and a 200-day moving average of $0.61. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.32 and a quick ratio of 2.11.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in ImmunoPrecise Antibodies stock. Baader Bank Aktiengesellschaft acquired a new position in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 26,961 shares of the company's stock, valued at approximately $29,000. Baader Bank Aktiengesellschaft owned about 0.06% of ImmunoPrecise Antibodies at the end of the most recent quarter. 6.70% of the stock is currently owned by hedge funds and other institutional investors.
ImmunoPrecise Antibodies Company Profile
(
Get Free Report)
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.
Further Reading
Before you consider ImmunoPrecise Antibodies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunoPrecise Antibodies wasn't on the list.
While ImmunoPrecise Antibodies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
